Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma

Abstract

MicroRNAs (miRNAs) are short noncoding RNAs that play critical roles in human malignancies and can be used as biomarkers for cancer. Until now, a number of biomarkers for prognosis of glioblastoma (GBM) have been reported in tumor tissues but only a few biomarkers in circulating fluid. Using a custom microarray, we previously identified 19 differentially expressed miRNAs in serum of patients with GBM. In this study, we investigated whether 3 of the 19 miRNAs in serum could be used as prognostic biomarkers for patients with GBM. We first validated the serum levels of 3 candidate miRNAs in an independent cohort of 24 GBM patients and 12 healthy volunteers by real-time quantitative reverse transcription PCR (qRT-PCR), and then evaluated the prognostic value of these miRNAs in a total of 36 GBM patients. The results show that the serum levels of the 3 miRNAs (miR-451a, miR-485-3p and miR-4298) determined by qRT-PCR are significantly different between 24 GBM patients and 12 healthy volunteers (all P <0.05) and are in concordance with the results of microarray analysis. High serum level of miR-451a is correlated with positive tumor O(6)-methylguanine-DNA methyltransferase (MGMT) expression (P = 0.040). Survival analysis showed that low serum miR-485-3p level is associated with poor progression-free survival (PFS) (P < 0.004) and overall survival (OS) (P < 0.023). Furthermore, univariate and multivariate Cox analyses demonstrated that that serum miR-485-3p expression is a significant independent prognostic factor for PFS and OS in GBM patients. In conclusion, serum miR-485-3p level is reduced and might be a potential prognostic biomarker in GBM patients.

<p>Long Noncoding RNA SNHG7, a Molecular Sponge for microRNA-485, Promotes the Aggressive Behavior of Cervical Cancer by Regulating PAK4</p>

“…MiR-485 is underexpressed in a variety of human cancers and exerts tumor-suppressive effects during cancer progression. [42][43][44][45][46][47][48][49][50][51][52] Herein, our results confirm that miR-485 is downregulated in both cervical cancer tissues and cell lines. Functionally, miR-485 was found to perform tumorsuppressive activities and was implicated in the control of malignant behavior of cervical cancer cells.…”

“…This analysis indicated that miR-485 contains a putative binding site for SNHG7 ( Figure 3B). MiR-485 is reported to be downregulated, and to exert tumor-suppressive effects in multiple human cancer types; [42][43][44][45][46][47][48][49][50][51][52] consequently, this miRNA was chosen for subsequent experiments. To test whether miR-485 can directly interact with the binding site in SNHG7, we generated the luciferase reporter plasmids harboring either the wild-type or mutant miR-485-binding site.…”

MicroRNA‑485 targets MACC1 and inhibits cervical cancer cell proliferation and invasion

“…For example, miR-485 is underexpressed in glioblastoma tissues, cell lines and blood serum. In addition, decreased miR-485 expression is correlated with poor progression-free survival and overall survival in patients with glioblastoma (18,19). In gastric cancer, the downregulation of miR-485 is strongly associated with tumor size, invasion depth, lymph node metastasis and tumor-node-metastasis (TNM) stage.…”

“…miR-485 is aberrantly expressed in several types of human cancer, including glioblastoma (18,19), gastric cancer (20) and lung adenocarcinoma (21). However, to the best of the authors' knowledge, the expression pattern, biological functions and underlying mechanisms of miR-485 in cervical cancer have not yet been investigated.…”

Circulating Micrornas Predict Survival of Patients with Tumors of Glial Origin

“…There are no literature reports of an involvement of miR-502-5p in CNS tumors, but it has been found up-regulated in the serum of patients with subarachnoid hemorrhage (SAH) ( Lai et al, 2017 ). Other Authors have conducted studies on serum, plasma, and whole blood samples of Glioblastoma or Low-grade glioma patients to isolate freely circulating, cellular and exosomal microRNA signatures ( Gozé et al, 2017 ; Regazzo et al, 2016 ; Roth et al, 2011 ; Wang et al, 2017b ). Although all signatures showed promising results, they could not correlate to survival.…”